Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Beta-caryophyllene (BCP) is a natural bicyclic sesquiterpene found in many essential oils, particularly clove oil, black pepper, and cannabis. Its use in supporting or treating osteoporosis is grounded in emerging scientific research, rather than traditional medicine. Several preclinical studies have explored the effects of BCP on bone health, with a focus on its anti-inflammatory, antioxidant, and cannabinoid receptor 2 (CB2) agonist properties.

Research published in peer-reviewed journals between 2016 and 2023 indicates that BCP can stimulate osteoblast activity (bone formation) and inhibit osteoclastogenesis (bone resorption) in cell and animal models. For instance, a 2017 study demonstrated that BCP could reduce bone loss in ovariectomized rats, a common model for postmenopausal osteoporosis, likely through CB2-mediated pathways that modulate inflammation and oxidative stress. Other studies have reported similar protective effects on bone density and microarchitecture.

However, there are currently no clinical trials confirming these benefits in humans. The evidence is promising but limited to preclinical data, and the underlying mechanisms are still being clarified. As such, the evidence rating is a 2, indicating some scientific basis but no robust clinical validation. Further human studies are needed to establish efficacy, safety, and optimal dosing before BCP can be recommended for osteoporosis treatment or prevention.

More about beta caryophyllene
More about Osteoporosis

Other ingredients used for Osteoporosis

Other health conditions supported by beta caryophyllene

Products containing beta caryophyllene